MK-6070

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Small cell lung cancerSmall cell lung cancer extensive stage

Phase 1

A Phase 1b/2 Open-Label Clinical Study to Evaluate the Safety and Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer

RecruitingCTIS2024-517926-25-00

Merck Sharp & Dohme LLCSmall cell lung cancer

Start: 2025-03-12Target: 40Updated: 2025-11-21

A Phase 1b/2 Open-label Study Evaluating different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-based regimens in First-line Extensive Stage Small Cell Lung Cancer

Not yet recruitingCTIS2025-521032-11-00

Merck Sharp & Dohme LLCSmall cell lung cancer extensive stage

Target: 12Updated: 2026-06-08